Current and ongoing trials with irinotecan in the United States.
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000069287:Capecitabine; D000068579:Celecoxib; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011355:Prodrugs / Q000627:therapeutic use*; D011720:Pyrazoles; D013449:Sulfonamides / Q000008:administration & dosage
D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D011355:Prodrugs; D011720:Pyrazoles; D013449:Sulfonamides; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D000077146:Irinotecan; D000068579:Celecoxib; D005472:Fluorouracil; D002166:Camptothecin